Differences in the length of Gag proteins among different HIV type 1 subtypes

AIDS Research and Human Retroviruses

Volumn 21, Issue 10, 2005, Pages 886-893

  Holguín, África ^a   Alvarez, Amparo ^a   Soriano, Vincent ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GAG PROTEIN; PROTEIN P10;

ADULT; ANALYTIC METHOD; ARTICLE; CLADISTICS; FEMALE; GENE DELETION; GENETIC CONSERVATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; STOP CODON; VIRUS CLASSIFICATION; VIRUS PARTICLE;

AMINO ACID MOTIFS; BASE SEQUENCE; DNA PRIMERS; GENE PRODUCTS, GAG; HIV-1;

EID: 31444445342     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2005.21.886     Document Type: Article

References (44)

1. Craven R and Parent L: Dynamic interactions of the Gag polyprotein. Curr Top Microbiol Immunol 1996;214:65-94.
2. von Schwedler U, Stuchell M, Muller B, et al.: The protein network of HIV budding. Cell 2003;114:701-713.
3. Kaplan A, Manchester M, and Swanstrom R: The activity of the protease of HIV-1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J Virol 1994;68:6782-6786.
4. Swanstrom R and Wills J: Retroviral gene expression. II. Synthesis, processing, and assembly of viral proteins. In: Retroviruses (Coffin JM, Hughes SH, and Varmus HE, eds). Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1997, pp. 263-334.
5. Jacks T, Power M, Masiarz F, Luciw P, Barr P, and Varmus H: Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 1998;331:280-283.
6. Zybarth G and Carter C: Domains upstream of the protease in HIV-1 gag-pol influence PI autoprocessing. J Virol 1995;69:3878-3884.
7. Tessmer U and Karausslich H: Cleavage of HIV-1 proteinase from the N-terminally adjacent P6* protein is essential for efficient gag polyprotein processing and viral infectivity. J Virol 1998;72:3459-3463.
8. Petit S, Sheng N, Tritch R, Erickson-Vitanen S, and Swanstrom R: The regulation of sequential processing of HIV-1 Gag by the viral protease. Adv Exp Med Biol 1998;436:15-25.
9. Russell R, Roldan A, Detorio M, Hu J, Wainberg M, and Liang C: Effects of a single amino acid substitution within the p2 region of HIV-1 on packaging of spliced viral RNA. J Virol 2003;77: 12986-12995.
10. Fu W and Rein A: Maturation of dimeric RNA of Moloney murine leukemia virus. J Virol 1993;67:5443-5449.
11. Feng Y, Campbell S, Harvin D, Ehresmann B, Ehresmann C, and Rein A: The HIV-1 Gag polyprotein has chaperone activity: Possible role in dimerization of genomic RNA and placement of tRNA on the primer binding site. J Virol 1999;73:4251-4256.
12. Feng Y, Copeland T, Henderson L, et al.: HIV-1 nucleocapsid protein induces maturation of dimeric retroviral RNA in vitro. Proc Natl Acad Sci USA 1996;93:7577-7581.
13. Muriaux D, De Rocquigny H, Roques B, and Paoletti J: NCp7 activates HIVLai RNA dimerization by converting a transient loop-loop complex into a stable dimer. J Biol Chem 1996;271:33686-33692.
14. Shehu-Xhilaga M, Kraeusslich H, Pettit S, et al: Proteolytic processing of the P2/nucleocapsid cleavage site is critical for HIV-1 RNA dimer maturation. J Virol 2001;75:9156-9164.
15. Petit S, Henderson G, Schiffer C, and Swanstrom R: Replacement of the pi amino acid of HIV-1 gag processing sites can inhibit or enhance the rate of cleavage by the viral protease. J Virol 2002; 76:10226-10233.
16. Addurahman S, Hoglund S, Goobar-Larsson L, and VahIne A: Selected amino acid substitutions in the C-terminal region of HIV-1 capsid protein affect virus assembly and release. J Gen Virol 2004; 85:2903-2913.
17. Goodenow M, Bloom G, Rose S, et al.: Naturally occurring amino acid polymorphisms in HIV-1 gag p7 (NC) and the C-cleavage site impact gag-pol processing by HIV-1 protease. Virology 2002;292: 137-149.
18. Liao W, Chiu H, and Wang C: Effects of mutations in an HIV-1 gag gene containing a 107-codon tandem repeat in the matrix region on assembly and processing of the protein product. J Med Virol 2004;74:528-535.
19. Tessmer U and Karausslich H: Cleavage of HIV-1 proteinase from the N-terminally adjacent P6* protein is essential for efficient gag polyprotein processing and viral infectivity. J Virol 1998;72: 3459-3463.
20. De Oliveira T, Engelbrecht S, van Rensburg E, et al.: Variability at HIV-1 subtype C protease cleavage sites and indication of viral fitness? J Virol 2003;77:9422-9430.
21. Myint L, Matsuda M, Matsuda Z, et al.: Gag non-cleavage site mutations contribute to full recovery of viral fitness in protease inhibitor-resistant HIV-1. Antimicrob Agents Chemother 2004;48: 444-452.
22. Doyon L, Croteau G, Thibeault D, Poulin F, Pilote L, and Lamarre D: Second locus involved in HIV-1 resistance to protease inhibitors. J Virol 1996;70:3736-3769.
23. Bally F, MartÌnez R, Peters S, Sudre P, and Telenti A: Polymorphisms of HIV-1 gag p7/p1 and p1/p6 cleavage sites: clinical significance and implications for resistance to protease inhibitors. AIDS Res Human Retroviruses 2000;16:1209-1213.
24. Barrie K, Pérez E, Lamers S, et al.: Natural variation in HIV-1 protease, gag p7 and p6, and protease cleavage sites within Gag/Pol polyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by HIV-1. Virology 1996;219:407-416.
25. Manguire M, Guinea R, Griffin P, et al.: Changes in HIV-1 gag at positions L449 and P453 are linked to 150V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol 2002;76:7398-7406.
26. Peters S, Muñoz M, Yerly S, et al.: Resistance to analog reverse transcriptase inhibitors mediated by HIV-1 P6 protein. J Virol 2001;75:9644-9653.
27. Kuiken C, Foley B, Hahn B, et al.: In: HIV Sequence Compendium (Kuiken C, Foley B, Hahn B, et al., eds). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2000.
28. Peeters M: Recombinant HIV sequences: Their role in the global epidemic. In: HIV Sequence Compendium (Kuiken C, Foley B, Hahn B et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2000, pp. 54-72.
29. Peeters M, Toure-Kane C, and Nkengasong J: Genetic diversity of HIV in Africa: Impact on diagnosis, treatment, vaccine development and trials. AIDS 2003;17:2547-2560.
30. Holguín A, Alvarez A, and Soriano V: Heterogeneous nature of HIV-1 recombinants spreading in Southern Europe. J Med Virol 2005;75:374-380.
31. Lospitao E, Álvarez A, Soriano V, and Holguín A: HIV-1 subtypes in Spain, 1995-2003: A retrospective analysis. HIV Med 2005;6: 313-320.
32. Holguín A, Alvarez A, Pena MJ, Artiles, Molina L, and Soriano V: High prevalence of non-B subtypes among HIV-positive immigrants in the Canary Islands, Spain. Implications for public health in Europe. HIV Clin Trials 2003;4:184-192.
33. Holguín A, Álvarez A, and Soriano V: High prevalence of subtype among HIV-infected immigrants attended in Madrid. AIDS 2002;16:1163-1170.
34. Mammano F, Petit C, and Clavel F: Resistance-associated loss of viral fitness in HIV-1: Phenotypic analysis of protease and gag co-evolution in protease inhibitor-treated patients. J Virol 1998;72: 7632-7637.
35. Gallego O, de Mendoza C, Corral A, and Soriano V: Changes in HIV-1 p7/p1/p6 gag gene in drug naive and pretreated patients. J Clin Microbiol 2003;41:1245-1247.
36. Russell R, Spira B, Liang C, and Wainberg M: The P2 spacer peptide in HIV-1 Gag plays a critical role in genome packaging specificity. 11th Conference on Retroviruses and Opportunistic Infections, 2004. Abstract 339.
37. Guo X, Hu J, Roldan A, Wainberg M, and Liang C: Attenuated membrane-binding of HIV-1 Gag protein caused by mutations of the CA-NC spacer sequences. 11th Conference on Retroviruses and Opportunistic Infections, 2004. Abstract 338.
38. Baldrich-Rubio E, Anagonou S, Stirrups K, et al.: A complex HIV type 1 A/G/J recombinant virus isolated from a seronegative patient with AIDS from Benin, West Africa. J Gen Virol 2001;82:1095-1106.
39. Holguín A, de Mendoza C, and Soriano V: Comparison of three commercial methods for quantification of plasma viraemia in clinical specimens belonging to non-B HIV-1 subtypes. Eur J Clin Microb Infect Dis 1999;18:256-259.
40. Descamps D, Apetrei C, Collin G, et al.: Naturally occurring decreased susceptibility of HIV-1 subtype G to protease inhibitors. AIDS 1998;12:1109-1111.
41. Holguin A and Soriano V: Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes. HIV Clin Trials 2002;3: 403-411.
42. Prater J: The impact of HIV-1 subtype on the clinical response on HAART. J. HIV Ther 2002;7:92-96.
43. Nicastri E, Sarmati L, dÉttorre G, et al.: Non-B HIV-1 subtypes: Replicative capacity and responses to antiretroviral therapy. AIDS Res Hum Retroviruses 2004;20:816-818.
44. Peeters M: Recombinant HIV sequences: Their role in the global epidemic. In: HIV Sequence Compendium (Kuiken C, Foley B, Hahn B, et al., eds). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2000, pp. 54-72.